En Stock y Listo para Envío desde EE.UU.
Envío GRATIS en pedidos de US$200+
Pago seguro mediante procesador de pagos encriptado
Estos productos son exclusivamente para investigación de laboratorio y no están destinados para uso médico. No están aprobados por la FDA para diagnosticar, tratar, curar o prevenir ninguna enfermedad. Al realizar su compra, usted certifica que serán utilizados exclusivamente para investigación y no para consumo humano o animal.
Overview GLOW Blend is a fixed-ratio co-formulation of three peptides selected for their non-overlapping but complementary roles in tissue-repair signaling. The 50 mg / 10 mg / 10 mg ratio (GHK-Cu : BPC-157 : TB-500) reflects the copper-tripeptide-dominant stack widely adopted across research peptide suppliers.[1][2] The rationale for combining these peptides is mechanistic: each component engages a distinct molecular target. GHK-Cu functions as a copper delivery vehicle and a master gene modulator, with reported >50% expression changes across approximately 31% of human genes.[9] BPC-157 activates the VEGFR2-Akt-eNOS cascade, driving angiogenesis and nitric-oxide-mediated repair.[5] TB-500 binds monomeric G-actin in a 1:1 stoichiometric complex via its LKKTETQ motif, enabling cytoskeletal reorganization required for cell migration.[6] Each component peptide has been individually evaluated in dozens of preclinical wound-healing, angiogenesis, and connective-tissue models. There are no published peer-reviewed studies of the three-peptide blend itself; investigators using the combined formulation infer additive activity from the individual literature. Researchers...
| Propiedad | Valor |
|---|---|
| Citas PubMed Referenciadas | 26 |
| Investigadores Colaboradores | 2 |
| Condiciones de Almacenamiento | Lyophilized blend at -20°C (long-term, up to 24 months). |
| Estándar de Pureza | ≥99% (HPLC verified, 3rd-party COA) |
| Solo para Uso en Investigación | No destinado al consumo humano. Solo para uso en investigación. |
GLOW Blend is a fixed-ratio co-formulation of three peptides selected for their non-overlapping but complementary roles in tissue-repair signaling. The 50 mg / 10 mg / 10 mg ratio (GHK-Cu : BPC-157 : TB-500) reflects the copper-tripeptide-dominant stack widely adopted across research peptide suppliers.[1][2]
The rationale for combining these peptides is mechanistic: each component engages a distinct molecular target. GHK-Cu functions as a copper delivery vehicle and a master gene modulator, with reported >50% expression changes across approximately 31% of human genes.[9] BPC-157 activates the VEGFR2-Akt-eNOS cascade, driving angiogenesis and nitric-oxide-mediated repair.[5] TB-500 binds monomeric G-actin in a 1:1 stoichiometric complex via its LKKTETQ motif, enabling cytoskeletal reorganization required for cell migration.[6]
Each component peptide has been individually evaluated in dozens of preclinical wound-healing, angiogenesis, and connective-tissue models. There are no published peer-reviewed studies of the three-peptide blend itself; investigators using the combined formulation infer additive activity from the individual literature. Researchers should refer to the individual product entries for full mechanism, applications, and citations.
The largest component, GHK-Cu, is the endogenous tripeptide Gly-His-Lys chelated to a Cu(II) ion. It "redox silences" copper to prevent Fenton-reaction toxicity while delivering Cu into cells for use by lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD. Connectivity Map analysis confirmed GHK modulates >4,000 genes, suppressing inflammatory/metastatic signatures and activating repair programs.[9][10] Stimulates collagen I/III, elastin, GAGs, and decorin synthesis with biphasic dose-response peaking near 10⁻⁹ M.[11]
BPC-157 binds and internalizes VEGFR2 on endothelial cells, triggering Akt phosphorylation and eNOS activation, yielding nitric oxide production essential for vascular repair (129–152% increased angiogenesis in chick chorioallantoic membrane and rat hind-limb ischemia models).[5] BPC-157 also activates the FAK-paxillin pathway and upregulates growth-hormone-receptor expression on tendon fibroblasts.[13]
The LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating polymerization into filamentous actin and enabling cytoskeletal reorganization required for cell motility.[6] TB-500 also engages F1-F0 ATP synthase on endothelial cells (KD ≈ 12 nM), forms a complex with integrin-linked kinase (ILK) and PINCH that activates Akt2, and upregulates MMP-2/MMP-9 to facilitate basement-membrane remodeling during angiogenesis.[14][15] Note: TB-500 lacks the N-terminal Ac-SDKP tetrapeptide of full-length Tβ4 and therefore does not contribute the anti-fibrotic TGF-β-modulating activity of the parent molecule.[16]
| Repair Axis | Primary Driver | Molecular Target |
|---|---|---|
| ECM synthesis & gene reset | GHK-Cu | Cu(II) delivery; ~31% genome modulated |
| Angiogenesis & NO signaling | BPC-157 | VEGFR2 → Akt → eNOS |
| Cell migration & cytoskeleton | TB-500 | G-actin 1:1 binding; ILK-PINCH-Akt2 |
| Antioxidant defense | GHK-Cu, TB-500 | Nrf2/Keap1; SOD upregulation |
| Anti-inflammatory | All three | NF-κB p65 phosphorylation blockade |
No published peer-reviewed pharmacokinetic or pharmacodynamic studies have evaluated the 50/10/10 blend as a single co-administered formulation. All mechanistic content is extrapolated from individual-component literature.
Laboratory studies using the GLOW combination — or the individual components in parallel — have explored:
Important: every cited study above used individual peptides, not the GLOW combination. Researchers using the blend should design experiments accordingly and not assume that the sum of single-agent effects has been validated in combination.
| Propiedad | Valor |
|---|---|
| Composition | 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 |
| Total Mass Per Vial | 70 mg lyophilized blend |
| GHK-Cu Component | Glycyl-L-Histidyl-L-Lysine-Cu(II); MW ~401.9 Da; CAS 89030-95-5 |
| BPC-157 Component | GEPPPGKPADDAGLV (pentadecapeptide); MW 1419.556 g/mol; CAS 137525-51-0 |
| TB-500 Component | Ac-LKKTETQ (N-acetylated heptapeptide, Tβ4 fragment 17–23); MW 889.018 g/mol; CAS 885340-08-9 |
| Appearance | White-to-pale-blue lyophilized powder (blue tint from GHK-Cu copper complex) |
| Classification | Multi-component research peptide blend |
| Purity Standard | |
|---|---|
| Identity Confirmation | |
| Counter-Ion | |
| Detection Methods |
No peer-reviewed studies have evaluated the GLOW 50/10/10 blend as a co-administered formulation. The studies below summarize key findings for each individual component. For full per-component data tables and clinical references, see the dedicated GHK-Cu, BPC-157, and TB-500 entries.
| Component | Representative Study | Key Finding |
|---|---|---|
| GHK-Cu | Canapp et al. (2003) — rat ischemic wounds | Wound size ↓ 64.5% vs 28.2% control; ↓ TNF-α, MMP-2/9 |
| GHK-Cu | Pickart & Margolina (2018) — gene-data review | Modulates >4,000 genes; resets expression toward "younger" state |
| BPC-157 | Hsieh et al. (2017) — rat hind-limb ischemia + CAM | 129–152% increased angiogenesis; VEGFR2-Akt-eNOS confirmed |
| BPC-157 | Staresinic et al. (2003) — rat Achilles transection | 10 µg/kg IP: improved AFI scores and load-to-failure 14–72d |
| TB-500 | Philp et al. (2003) — db/db diabetic and aged mice | LKKTETQ fragment promoted dermal repair comparable to full Tβ4 |
| TB-500 (parent Tβ4) | Bock-Marquette et al. (2004) — Nature | Tβ4 activates ILK → cardiac cell migration, survival, repair |
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
Loren Pickart, PhD, was a biochemist at the University of California, San Francisco (UCSF), and the discoverer of GHK-Cu — the dominant component (50 mg, 71.4%) of the GLOW blend. He isolated GHK from human plasma albumin in 1973 and identified its ability to make old liver tissue synthesize younger protein profiles. He founded ProCyte Corporation (1985–1991) and Skin Biology, Inc. to commercialize copper peptide products. In later years, he used the Broad Institute Connectivity Map to demonstrate GHK modulates >4,000 human genes. Loren Pickart is being referenced as one of the leading scientists involved in the research and development of GHK-Cu, the principal mass component of this blend. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
Ver Perfil Completo del Investigador →Predrag Sikiric, MD, PhD, is a Professor at the Department of Pharmacology, School of Medicine, University of Zagreb, Croatia. Dr. Sikiric is the lead researcher who originally isolated BPC-157 from human gastric juice in 1993, and is responsible for over 80% of the published BPC-157 literature. His work established the cytoprotection/organoprotection framework, demonstrating BPC-157's pleiotropic effects on organ healing. Predrag Sikiric is being referenced as one of the leading scientists involved in the research and development of BPC-157, a component of this blend. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
Ver Perfil Completo del Investigador →Dr. Predrag Sikiric is being referenced as one of the leading scientists involved in the research and development of GLOW. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.
DOISikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection. Current Pharmaceutical Design. 2020;26(25):3024-3044.
DOIGoldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
DOIPickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may Prevent Oxidative Stress in Skin. Cosmetics. 2015;2(3):236-247.
DOIHsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. Journal of Molecular Medicine. 2017;95(3):323-333.
DOIXing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology. 2021;12:767785.
DOIU.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding. FDA.gov. Updated 2023.
FDA.govWorld Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025.
WADAPickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the human genome to health. BioMed Research International. 2014;2014:151479.
DOIPickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways. BioMed Research International. 2015;2015:648108.
DOIMaquart FX, Pickart L, et al. Stimulation of collagen synthesis by GHK-Cu. FEBS Letters. 1988;238(2):343-346.
DOISchlosser N. BPC-157: A Polyproline II Helix Engages SH3 Domains of Src Family Kinases. 2025.
PubMedChang CH, et al. BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077.
DOIBock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472.
DOISosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta 4. The FASEB Journal. 2010;24(7):2144-2151.
DOIBock-Marquette I, et al. Thymosin beta-4 denotes new directions for anti-aging therapies. International Immunopharmacology. 2023;116:109741.
DOICanapp SO Jr, et al. Topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery. 2003;32(6):515-523.
DOIPhilp D, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair. Wound Repair and Regeneration. 2003;11(1):19-24.
DOIStaresinic M, et al. BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research. 2003;21(6):976-983.
DOIBadenhorst T, et al. Effects of GHK-Cu on MMP and TIMP Expression. Journal of Aging Science. 2016;4(3):166.
DOISmart N, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.
DOIKuceki G, et al. Enhanced hair regrowth with minoxidil-dutasteride-copper peptides for androgenetic alopecia. JAAD International. 2025;20:38-40.
DOIGoldstein AL, et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421-429.
DOISever M, et al. BPC 157 counteracts liver fibrosis. Journal of Physiology and Pharmacology. 2019;70(3):391-400.
PubMedShah R, et al. Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Liver Injury. Oxidative Medicine and Cellular Longevity. 2018;2018:9630175.
DOISosne G, Dunn SP, Kim C. Thymosin β4 Improves Severe Dry Eye in a Phase 2 Randomized Trial. Cornea. 2015;34(5):491-496.
DOISolo para Uso en Investigación (RUO). No destinado al consumo humano, uso clínico, ni como medicamento, alimento, cosmético o dispositivo médico. Este producto no ha sido evaluado por la FDA y se suministra exclusivamente para investigación de laboratorio in vitro por profesionales calificados.
Each lot is independently tested by accredited third-party laboratories (ISO 17025) at 99%+ purity.
Lyophilized blend at -20°C (long-term, up to 24 months). Reconstituted: -80°C up to 6 months or 2-8°C ≤14 days. Stable pH 5.0–7.0. Avoid chelators (EDTA, carnosine, Vitamin C strip copper from GHK-Cu).
Lyophilized Powder: Store at -20°C for long-term stability (up to 24 months). White-to-pale-blue powder; the faint blue tint reflects the GHK-Cu copper complex (50 mg fraction). Hygroscopic — keep tightly sealed under inert gas (N₂ or Argon).
Reconstituted Solution: Store aliquots at -80°C for up to 6 months. Refrigerated (2–8°C) solutions should be used within 14 days due to BPC-157 and TB-500 hydrolysis kinetics. Reconstitute with bacteriostatic water or sterile saline using gentle swirling — do not vortex or shake aggressively.
pH Stability: Stable in the range of pH 5.0–7.0. Below pH 4 or above pH 9, GHK-Cu may dissociate and release free copper, which can catalyze oxidative degradation of BPC-157 and TB-500.
Critical Incompatibilities: Do not co-formulate with EDTA, carnosine, Vitamin C, or other strong chelators — these strip Cu(II) from GHK-Cu and abolish its activity.
Component Purity: ≥98% per peptide by HPLC; identity by mass spectrometry; TFA-free preferred for biological-grade research.
Handling: Allow vials to warm to room temperature before opening to prevent moisture condensation onto the lyophilized cake. Standard aseptic technique. Discard any solution that appears cloudy or contains particulate matter.
Common research questions about GLOW — purity, handling, COA documentation, and published-research context.
Verified researcher feedback on GLOW — purity, COA accuracy, shipping, and lab support.
We were running comparative recovery-model work that required all three components and were tired of reconstituting separately. The GLOW blend solved that, and the lot-specific component breakdown on the COA is exactly what our IRB-equivalent committee wanted to see.
Lyophilized cake is uniform, reconstituted cleanly. Identity confirmation matches the documented blend. Pure US Peptides has been my go-to for this category.
Excellent product. The fact that every component is HPLC-tested individually before blending is what sold me. Documentation transparency is significantly above what competitors offer.
Product quality is excellent. My only minor wish: a printed insert documenting reconstitution best practices. Otherwise flawless — vials sealed, COA accurate, shipping fast.
Used in our pre-clinical tissue-recovery work for two months. Consistent product across two separate lots. Customer service was fast when I had a question on storage windows.
Shipping was overnight, vials arrived in pristine condition. The blend reconstitutes without haze — clearly properly lyophilized. Documentation pack was comprehensive.
Reviews submitted by verified research-buyer customers via post-purchase email. Reviewer names are shown with initials and role to protect privacy. All feedback covers product purity, documentation, and shipping — never application methodology.
